GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$41.18 USD
+0.86 (2.13%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $41.19 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.18 USD
+0.86 (2.13%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $41.19 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum B VGM
Zacks News
Why GSK (GSK) Outpaced the Stock Market Today
by Zacks Equity Research
In the most recent trading session, GSK (GSK) closed at $37.56, indicating a +0.59% shift from the previous trading day.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
GSK (GSK) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
GSK (GSK) closed at $37.10 in the latest trading session, marking a +1.23% move from the prior day.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Moderna (MRNA) to Advance COVID/Flu Combo Jab to Late-Stage Study
by Zacks Equity Research
Moderna's (MRNA) intends to start the late-stage study on its COVID-19-influenza combination vaccine candidate before year-end. A commercial launch is expected in 2025.
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AstraZeneca (AZN) Settles Heartburn Drugs Lawsuits for $425M
by Zacks Equity Research
AstraZeneca (AZN) agrees to pay $425 million to settle lawsuits related to heartburn drugs, Nexium and Prilosec.
GSK (GSK) Stock Moves -0.55%: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $35.89 in the latest trading session, marking a -0.55% move from the prior day.
GSK (GSK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $36.09 in the latest trading session, marking a -0.44% move from the prior day.
GSK (GSK) Stock Moves -1.14%: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $37.28, moving -1.14% from the previous trading session.
GSK (GSK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $37.71, marking a +0.75% move from the previous day.
CDC Recommends Pfizer's (PFE) RSV Jab to Protect Newborns
by Zacks Equity Research
Pfizer's (PFE) Abrysvo has been recommended by the CDC for preventing RSV in infants by immunizing pregnant women, during weeks 32-36 of pregnancy.
Biotech Stock Roundup: GSK's Drug Approval, MRNA's Vaccine News, PTCT & SPRY Down
by Zacks Equity Research
Regulatory updates from GSK and Moderna (MRNA) are in focus in the biotech sector.
GSK (GSK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $37.48, moving +0.35% from the previous trading session.
Incyte (INCY) Down on FDA Nod for Another Myelofibrosis Drug
by Zacks Equity Research
Incyte (INCY) declines on potential competition for lead drug Jakafi from Ojjaara for the treatment of intermediate or high-risk myelofibrosis.
GSK's Momelotinib Gets FDA Nod for Myelofibrosis-Related Anemia
by Zacks Equity Research
GSK's Ojjaara (momelotinib) is the first and the only drug approved to treat myelofibrosis patients with anemia in the United States.
Moderna (MRNA) Posts '28 Biz View, Up 3% on Upbeat Flu Jab Data
by Zacks Equity Research
Moderna's (MRNA) reformulated influenza vaccine candidate meets the primary endpoint in a late-stage study. It expects to launch up to 15 new products in the next five years.
GSK (GSK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $36.76, marking a -0.27% move from the previous day.
AstraZeneca (AZN) Posts Upbeat Data on Lung Cancer Drug Combo
by Zacks Equity Research
Data from a late-stage study shows that AstraZeneca's (AZN) Tagrisso combined with chemotherapy cut the risk of disease progression or death by 38% in certain lung cancer patients.
GSK (GSK) Moves 5.5% Higher: Will This Strength Last?
by Zacks Equity Research
GSK (GSK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
GSK (GSK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $34.64 in the latest trading session, marking a +0.67% move from the prior day.
Is WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DNL
SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why
by Zacks Equity Research
SCYNEXIS' (SCYX) shares soar 134% year to date, owing to partnership with big wig GSK plc for the development of its antifungal tablet, Brexafemme.
Why Is Intercept (ICPT) Up 0.6% Since Last Earnings Report?
by Zacks Equity Research
Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead (GILD) Gets FDA Nod for Veklury for Hepatic Impairment
by Zacks Equity Research
Gilead's (GILD) anti-viral treatment Veklury gets FDA approval for the treatment of COVID-19 in patients with mild, moderate or severe hepatic impairment.